EUVIMEDEUVIMED entdecken
Fallbericht

Great Expectations: Semaglutide as Antidiabetic Weight Management in a Psychiatric Hospital

Krysta Shannon iD, Grace Shyh

Journal of Pharmacy Practice · 2025-06 · 38 (3) · 351-356

DOI: 10.1177/08971900241294122 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Pharmacy Practice, online erschienen am 22.10.2024. Verfasst von Krysta Shannon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy Manager, NewYork-Presbyterian Hospital, New York, NY, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Hypoglycemic Agents, Diabetes Mellitus, Type 2, Hospitals, Psychiatric. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This report explores the potential role of glucagon-like peptide 1 (GLP-1) receptor agonists in minimizing the metabolic side effects of psychotropic medications in patients with underlying type 2 diabetes (T2D) in inpatient psychiatric settings. The introduction of novel antidiabetic medications such as GLP-1 receptor agonists has broadened the options for managing metabolic disorders, particularly T2D. These medications not only offer effective glycemic control but also provide cardiovascular and renal benefits and help with weight management. Given the tendency of psychotropic medications to cause weight gain and metabolic complications, this report presents 2 cases where weekly doses of semaglutide improved blood glucose levels and prevented weight gain in patients receiving chronic psychotropic medications. Integrating GLP-1 receptor agonists into inpatient psychiatric care can help mitigate the metabolic adverse effects of psychotropic medications. However, considerations such as cost, accessibility, and institutional formulary restrictions are essential to ensure comprehensive patient care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesHypoglycemic AgentsDiabetes Mellitus, Type 2Hospitals, PsychiatricWeight GainHumansMiddle AgedMaleFemaleBlood GlucosePsychotropic DrugsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

diabetes mellitusglucagon-like peptide 1 (GLP-1) receptor agonistsmetabolic disorderspsychotropic medication

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsBlood GlucosePsychotropic DrugsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Clinical Pharmacy Manager, NewYork-Presbyterian Hospital, New York, NY, USA.

ORCID-Profile: Krysta Shannon

Zitieren

APA

Shannon, K., & Shyh, G. (2025). Great Expectations: Semaglutide as Antidiabetic Weight Management in a Psychiatric Hospital. Journal of Pharmacy Practice, 38(3), 351-356. https://doi.org/10.1177/08971900241294122

Vancouver

Shannon K, Shyh G. Great Expectations: Semaglutide as Antidiabetic Weight Management in a Psychiatric Hospital. Journal of Pharmacy Practice. 2025;38(3):351-356. doi:10.1177/08971900241294122

BibTeX
@article{Shannon2025,
  author = {Shannon, Krysta and Shyh, Grace},
  title = {Great Expectations: Semaglutide as Antidiabetic Weight Management in a Psychiatric Hospital},
  journal = {Journal of Pharmacy Practice},
  year = {2025},
  volume = {38},
  number = {3},
  pages = {351--356},
  doi = {10.1177/08971900241294122}
}
Kostenlos starten →